MedinCell has launched a COVID-19 research initiative based on its experience to formulate long-acting injectable Ivermectin

April 6, 2020

First in-vitro validation of impact of Ivermectin on Covid-19 by Australian researchers

• Researchers at Monash University in Melbourne, Australia, have published last Friday a study showing that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ∼5000-fold reduction in virus at 48h in cell culture1.
• Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
• MedinCell has published data showing that long-acting formulations of Ivermectin can be designed with varying doses and durations with its BEPO® technology2 and is already leading a program aiming at developing a 3-Month injectable product to fight malaria3.
• MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
• Future clinical studies will have to confirm the action of Ivermectin on Covid-19 virus, and the potential effectiveness of a long-acting injectable on its prevention and therefore breaking the chain of transmission.
• In case of positive results, a BEPO® technology based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.

1 The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro – Leon Caly, Julian D. Druce, Mike G. Catton, David A. Jans,
Kylie M. Wagstaff – Antiviral Research, 3 April 2020
2 Source: BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery
kinetics modulation – Christophe Roberge, Jean-Manuel Cros, Juliette Serindoux, Marie-Emérentienne Cagnon, Rémi Samuel, Tjasa Vrlinic,
Pierre Berto, Anthony Rech, Joël Richard, Adolfo Lopez-Noriega – Journal of Controlled Release, Volume 319, 10 March 2020, Pages 416-427
3 Company press release: MedinCell receives $ 6.4 million grant from Unitaid to fight Malaria – 03.25.2020

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.